William Blair analyst Max Smock has reiterated their bullish stance on MEDP stock, giving a Buy rating on April 9.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Max Smock’s rating is based on Medpace Holdings’ strong financial performance in the first quarter, where the company exceeded revenue expectations, achieving $559 million compared to the anticipated $530 million. This was driven by both direct fee and pass-through revenues surpassing targets. Despite a slight miss in EBITDA, the earnings per share (EPS) significantly outperformed expectations, largely due to lower-than-expected income tax expenses.
Moreover, Medpace’s decision to raise its 2025 sales and EPS outlooks reflects confidence in its future growth prospects. The company also demonstrated shareholder value commitment by repurchasing $390 million worth of shares and approving an additional $1 billion for its stock repurchase program. These strategic moves, along with the raised guidance, underpin Max Smock’s positive outlook and Buy rating for Medpace Holdings.
In another report released on April 9, Mizuho Securities also maintained a Buy rating on the stock with a $355.00 price target.